Select Committee on Science and Technology Written Evidence

Annex 1


1.A study to identify genes associated with abnormal naevi (by implication therefore, melanoma susceptibility genes) and cutaneous ageing.
2.Diabetes. Obesity, intrauterine growth and atherosclerosis: the fetal origins hypotheses.
3.Inadequate sperm: a molecular biological investigation of the commonest endocrine disorder.
4.Genetic and molecular investigation of ischaemic heart disease using family based studies.
5.Identification of the genetic predisposition to diabetic nephropathy.
6.A genome wide search for susceptibility genes for nephropathy and albuminuria employing novel studies in type two diabetes.
7.Mapping of genetic susceptibility for insulin-dependent (type 1) diabetes mellitus in the Northern Ireland population.
8.The study of inherited ophthalmic disorders.
9.Studies of inherited breast cancer and fragile X.
10.Studies of familial hypocholestemia.
11.Studies on tylosis, familial colonic polyps and colorectal cancer and Peutz-Jaeger syndrome.
12.Identification of genes relevant to the early detection of pancreatic cancer.
13.Investigation of genetic risk factors for lung cancer.
14.Concerted action on polyposis coli.
15.Clinical diagnosis of hereditary non-polyposis colon cancer: managing perceived risk.
16.Isolation and characterisation of candidate tylosis oesophageal cancer genes.
17.A randomised controlled trial of colorectal polyp and cancer prevention using aspirin and resistant starch in carriers of hereditary non-polyposis colon cancer (CAPP-2).
18.Establishment of a European registry for hereditary pancreatitis and familial pancreatic cancer.
19.The molecular pathogenesis of hereditary pancreatitis and familial pancreatic cancer.
20.Identification of new genes responsible for pancreatic cancer.
21.Metastasis genes in prostate cancer.
22.Chromosome re-duplication in cervical neoplasia.
23.Numerical chromosome aberrations and tumour ploidy in ovarian neoplasia.
24.The role of human papillomavirus infection in the development of vulval neoplasia.
25.The role of human papillomavirus infection in the development of cervical glandular neoplasia.
26.Novel metastasis-suppressing genes in human prostate cancer.
27.Cleft lip palate linkage project.
28.Genetic pathology of bronchial epithelium in tumour-bearing lungs and the relationship to metaplasia and dysplasia.
29.An investigation into the role of DNA repair genes and telomerase activity in non-small cell lung carcinomas.
30.Early molecular events in the pathogenesis of lung cancer.
31.The role of transposable elements in the pathogenesis of lung cancer.
32.Molecular pathogenesis of lung cancer.
33.Isolation and characterisation of tylosis oesophageal cancer genes.
34.Further characterisation of the physical map of the region of chromosome 17q25 containing the tylosis.
35.Oesophageal cancer (TOC) genes and identification of additional candidate TOC genes.
36.Molecular diagnosis of dysplastic lesions and oral cancer.
37.Natural history of transfusion-acquired HCV infection: identification of host and viral genetic predictors of clinical outcome.
38.National molecular genetics register of familial pancreatic cancer.
39.Prognostic value of tumour DNA in serum in oral cancer.
40.Genetic risk factors for alcoholic liver disease.
41.Mutation studies in propionic acidaemia and methylmalonic aciduria.
42.Environmental and genetic predisposing factors for chronic disease and cancer (EPIC study).
43.Ely study of type 2 diabetes.
44.Investigation of the prevalence of germline mutations in BRCA1 and BRCA2 in women with breast cancer diagnosed before 30 years of age or with a strong family history.
45.A population based study of familial breast cancer in East Anglia.
46.Evaluating services for women with familial risk of breast cancer; consumer push or practitioner pull in primary care consultations.
47.An assessment of screening for fragile X syndrome.
48.Screening for cystic fibrosis.
49.Evaluation of molecular pre-natal diagnosis for Down's syndrome.
50.Genetic services in pregnancy—an evaluation of the genetic family register approach.
51.Detection of fetal abnormality at different gestations: impact on parents and service implications.
52.A randomised controlled trial of the effect of a practice-based genetic screening facilitator.
53.Genetic influences on intra-uterine growth and their relationship to non insulin-dependent diabetes and vascular disease.
54.Evaluation of genetic profiling for predicting bone marrow transplant.
55.Development and clinical application of a test to detect cryptic cytogenetic abnormalities in patients with idiopathic retardation.
56.Predictive genotyping for platelet transfusion resistance in multi-transfused patients.
57.Identifying the contribution of micro-environmental and genetic influences to osteolysis around joint replacements.
58.The molecular genetics of non insulin-dependent diabetes (NIDDM) and its relationship with intra-uterine development.
59.Use of biomarkers in classifying, treating and preventing the secondary progression of osteoarthritis.
60.National Case Registration of pre- and post-natal cytogenetic diagnosis of chromosomal anomalies causing Down's Syndrome (NDSCR).
61.The chromosome abnormality database.
62.Development and optimisation of methods to detect germline mutations and microsatellite instability in HNPCC families; and finding new colon cancer genes in non-HNPCC families.
63.Epidemiological study of BRCA1 and BRCA2 carriers.
64.UKCCCR national familial ovarian cancer screening study.
65. Risk of testis cancer in the families of patients with bilateral testicular germ-cell malignancy.

Yvette Cooper MP
Minister for Public Health

24 October 2000

previous page contents next page

House of Lords home page Parliament home page House of Commons home page search page enquiries index

© Parliamentary copyright 2000